
BioPorto Investor Relations Material
Latest events

Q1 2025
BioPorto

Q1 2025
8 May, 2025

Q4 2024
20 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from BioPorto
Access all reports
BioPorto A/S is a global biotech company that specializes in the development and manufacturing of in-vitro diagnostic tests and antibodies for both research and clinical applications. The company's diagnostics products are primarily based on a patented proprietary technology platform called MoAb®. The Company's products are used in research, including preclinical studies and clinical trials, as well as in diagnosis procedures to detect infectious diseases, cancer, autoimmune disorders and other diseases. BioPorto A/S is based in Hellerup, Denmark.
Key slides for BioPorto
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
BIOPOR
Country
🇩🇰 Denmark